Publication:
Comparative overview of ST-elevation myocardial infarction epidemiology, demographics, management, and outcomes in five Asia-Pacific countries: a meta-analysis

Simple item page
dc.contributor.authorPaul Jie Wen Tern
dc.contributor.authorAaron Kwun Hang Ho
dc.contributor.authorRehena Sultana
dc.contributor.authorYoungkeun Ahn
dc.contributor.authorWael Almahmeed
dc.contributor.authorDavid Brieger
dc.contributor.authorDerek P Chew
dc.contributor.authorAlan Yean Yip Fong
dc.contributor.authorJinyong Hwang
dc.contributor.authorYongcheol Kim
dc.contributor.authorIssei Komuro
dc.contributor.authorKoji Maemura
dc.contributor.authorRosli Mohd-Ali
dc.contributor.authorDavid Kwang Leng Quek
dc.contributor.authorChristopher Reid
dc.contributor.authorJack Wei Chieh Tan
dc.contributor.authorWan Azman Wan-Ahmad
dc.contributor.authorSatoshi Yasuda
dc.contributor.authorKhung Keong Yeo
dc.date.accessioned2024-07-30T08:42:17Z
dc.date.available2024-07-30T08:42:17Z
dc.date.issued2020
dc.description.abstractThe aim of this study is to gain insight into the differences in demographics of ST-elevation myocardial infarction (STEMI) patients in Asia-Pacific, as well as inter-country variation in treatment and mortality outcomes. Systematic review of published studies and reports from known registries in Australia, Japan, Korea, Singapore, and Malaysia that began data collection after the year 2000. Supplementary self-report survey questionnaire on public health data answered by representative cardiologists working in these countries. Twenty studies comprising of 158 420 patients were included in the meta-analysis. The mean age was 61.6 years. Chronic kidney disease prevalence was higher in Japan, while dyslipidaemia was low in Korea. Use of aspirin, P2Y12 inhibitors, and statins were high throughout, but ACEi/ARB and β-blocker prescriptions were lower in Japan and Malaysia. Reperfusion strategies varied greatly, with high rates of primary percutaneous coronary intervention (pPCI) in Korea (91.6%), whilst Malaysia relies far more on fibrinolysis (72.6%) than pPCI (9.6%). Similarly, mortality differed, with 1-year mortality from STEMI was considerably greater in Malaysia (17.9%) and Singapore (11.2%) than in Korea (8.1%), Australia (7.8%), and Japan (6.2%). The countries were broadly similar in development and public health indices. Singapore has the highest gross national income and total healthcare expenditure per capita, whilst Malaysia has the lowest. Primary PCI is available in all countries 24/7/365. Despite broadly comparable public health systems, differences exist in patient profile, in-hospital treatment, and mortality outcomes in these five countries. Our study reveals areas for improvements. The authors advocate further registry-based multi-country comparative studies focused on the Asia-Pacific region.
dc.identifier.doi10.1093/ehjqcco/qcaa057
dc.identifier.urihttps://academic.oup.com/ehjqcco/article/7/1/6/5862633
dc.identifier.urihttps://repository.nih.gov.my/handle/123456789/757
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofEuropean Heart Journal - Quality of Care and Clinical Outcomes
dc.relation.issn1522-9645
dc.relation.journalEuropean Heart Journal
dc.subjectSTEMI
dc.subjectSystematic review
dc.subjectDemographics
dc.subjectTreatment
dc.subjectMortality
dc.subjectAsia-Pacific
dc.titleComparative overview of ST-elevation myocardial infarction epidemiology, demographics, management, and outcomes in five Asia-Pacific countries: a meta-analysis
dc.typejournal-article
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.volume7
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
NIH20200179.pdf
Size:
2.43 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Selected Article of Journal (ICR)